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Optimal Therapy for
ST-Segment Elevation
Myocardial Infarction
The Role of Residual Thrombus*
Robert J. Applegate, MD
Winston-Salem, North Carolina
Strategies that enhance functional reperfusion and translate
into better clinical outcomes for ST-segment elevation
myocardial infarction (STEMI) remain the holy grail of
reperfusion therapy. In the absence of complete understand-
ing of the vascular and cellular processes that are initiated
with plaque rupture and thrombotic coronary artery occlu-
sion, we have had to rely on therapies that shorten the
duration of occlusion as well as result in effective thrombol-
ysis. Because the initial events of a myocardial infarction
appear to be mediated by acute thrombosis, it would seem
logical that effective therapy would focus on pharmacologic
strategies that would directly result in clot lysis, and/or
enhance intrinsic fibrinolysis. Thrombolytic agents admin-
istered soon after the onset of an acute myocardial infarction
achieve reperfusion in a majority of patients and save lives.
Moreover, fibrin-specific thrombolytic agents achieve higher
rates of vessel patency and are associated with lower mortality
rates than non–fibrin-specific agents such as streptokinase.
Finally, the ease of administration and life-saving characteris-
tics of thrombolytics thrust this therapy into position as
first-line treatment for an acute myocardial infarction in the
1980s and 1990s, and as a Class I, Level of Evidence: A,
recommendation for STEMI (1).
See page 1867
However, although the majority of patients receiving
thrombolytics achieve angiographic and clinical evidence of
reperfusion, a sizable minority achieve neither. This latter
group remains a clinical challenge and is the Achilles heel of
thrombolytic therapy. Although associated with inherent
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travenously, primary percutaneous coronary intervention
(PCI) achieves higher rates of angiographic and clinical
reperfusion than thrombolytic therapy and has supplanted
thrombolytic therapy as first-line treatment for acute myo-
cardial infarction (when there are not substantial delays in
obtaining primary PCI) (2).
The clinical success of these 2 reperfusion strategies
depends not only on achieving recanalization/reperfusion of
an occluded vessel, but also on maintenance of patency with
adjunctive anticoagulant and antiplatelet therapy. A thor-
ough review and discussion of the clinical evidence evalu-
ating the relative benefits of different adjunctive strategies is
beyond the scope of this editorial. However, it is important
to understand that a strictly pharmacologic approach to an
acute myocardial infarction results in complex and dynamic
effects of thrombosis and fibrinolysis that were not entirely
understood when thrombolytic therapy was initially pro-
posed and introduced into clinical practice. The most
important facet of this complex interaction of fibrinolytics
with the coagulation system is the prothrombotic effects of
fibrinolytics, with activation of platelets accompanying fi-
brinolysis. This will become important as shall be discussed.
It is also important to recognize that epicardial reperfu-
sion as measured traditionally by Thrombolysis In Myocar-
dial Infarction (TIMI) flow grade, or TIMI frame count (3),
is not synonymous with tissue perfusion, that is, at the
myocyte (4,5). This is evidenced by the variability in clinical
outcomes of patients with TIMI flow grade 3, or the
restoration of normal epicardial flow (6). Within this group
are patients who have clinical outcomes similar to patients
who had less successful restoration of epicardial flow. These
patients are characterized by TIMI flow grade 3 epicardial
flow but absence of myocardial blush, a surrogate for tissue
perfusion at the microvascular level (6). The mechanisms
responsible for this apparent dichotomy in epicardial and
microvascular flow are under active clinical investigation,
but remain incompletely elucidated. Potential mechanisms
include the presence of embolized platelet-rich thrombi,
leukocyte activation, and local accumulation of inflamma-
tory mediators.
With the inherent delays in PCI and lack of universal
availability, strategies to initiate the process of reperfusion
before facilitated PCI, or more simply “drip and ship,” have
gained great enthusiasm. Several large randomized control
trials have been designed and completed to test the hypoth-
esis that pharmacologic therapy could be given quickly after
the initial identification of an acute myocardial infarction,
while the patient is being prepared for PCI (7,8). Quite
surprisingly, these studies have consistently observed just
the opposite. That is, patients receiving facilitated PCI did
not fare better, and if full-dose thrombolytics and glyco-
protein IIb/IIIa inhibitors (GPI) were given, there was a
substantially higher rate of bleeding, including fatal bleed-
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who have scrambled for explanations.
Some would point out that similar observations were
made in the TIMI II-A (Thrombolysis In Myocardial
Infarction, phase II-A) trial in which thrombolytic therapy
followed by early catheterization and PCI (48 h) was
accompanied by higher adverse rates of clinical outcomes
than if the PCI were performed after 48 h (9). However,
TIMI II-A was completed in the pre-GPI era, and it was
presumed that inadequate platelet inhibition was responsi-
ble for the apparent poor results observed in TIMI II-A
given the now well-recognized platelet activation by throm-
bolytics (10). An alternative explanation has been suggested
by Stone and Gersh (11), who suggested that the lack of
benefit of facilitated PCI versus primary PCI alone for
STEMI could be explained by the delays in PCI inherent to
randomized central trials. In support of this, they point out
that median time from symptom onset to balloon angio-
plasty was 3.5 h for all trials in aggregate. The potential for
myocardial salvage is much less at this time than within the
first hour or 2, so it should not be surprising that differences
in outcomes were not detected.
In this issue of the Journal, Zalewski et al. (12) present a
substudy of the ASSENT-4 PCI (Assessment of the Safety
and Efficacy of a New Treatment Strategy With Percuta-
neous Coronary Intervention) trial comparing primary PCI
for STEMI to tenecteplase-facilitated PCI. These investi-
gators retrospectively reviewed all angiograms obtained
from patients enrolled in the ASSENT-4 PCI trial (13).
They assessed vessel patency using TIMI flow grade and
frame counts and evaluated for the presence of thrombus.
For this, the investigators defined thrombus burden as a
composite measure of TIMI thrombus grade (2), slow
flow without dissection or embolus, and/or angiographic
evidence of distal embolization. The principal observation
of this post hoc analysis was that despite a higher incidence
of infarct vessel patency at the time of the initial angiogram
with facilitated PCI, at case end these patients had a higher
thrombus burden than those who underwent primary PCI
alone. Moreover, facilitated PCI combined with thrombus
burden was an independent predictor of higher mortality at
90 days (odds ratio: 2.43, 95% confidence interval: 1.30 to
4.51). The investigators speculated that the prothrombotic
characteristics of tenecteplase with suboptimal anticoagula-
tion and antiplatelet therapies led to resistant thrombus that
was more likely to impair tissue perfusion despite the
apparent higher rates of initial restoration of epicardial flow
than primary PCI alone (10).
These observations from the ASSENT-4 PCI trial pro-
vide important insights into the potential mechanisms
responsible for the lack of benefit overall of the facilitated
PCI strategy in ASSENT-4 PCI. Data from several lines of
clinical investigation indicate that distal embolization is
associated with impaired tissue perfusion, and that impaired
tissue perfusion is associated with worse clinical outcomes,
all things otherwise being equal. Thus, the greater thrombusburden and distal embolization in those undergoing facili-
tated PCI would be expected to have worse clinical out-
comes than in those without these features, in other words,
primary PCI alone. Although the exact composition of
these “resistant thrombi” were not evaluated in this study,
the investigators postulated that they might be similar to the
highly organized and fibrin-rich thrombi recovered from
distal embolic protection devices at the time of primary PCI
(14). Although this hypothesis is appealing, it is difficult to
understand why patients receiving thrombolytics (facilitated
PCI) should have thrombus of similar composition to
patients not receiving thrombolytics (primary PCI with
embolic protection), in whom fibrinolytic-mediated platelet
activation should not be present. Further studies will need
to determine if these resistant thrombi are erythrocyte- or
platelet-rich, or a combination of both, and what causative
role they may have in limiting tissue perfusion.
Another point of potential concern in accepting the role
of resistant thrombi as the sole, if not principle, explanation
for the apparent lack of benefit of facilitated PCI is that no
benefit was observed in 3 trials in which half-dose lytics
were administered along with full-dose GPI. Presumably,
GPI coadministration should have neutralized fibrinolytic-
mediated platelet activation in these studies. Yet, no appar-
ent benefit with regard to clinical outcomes were observed
in these 3 trials using this strategy (7,15,16). Clearly, these
observations from ASSENT-4 PCI are hypothesis-
generating and should stimulate further clinical evaluation
into the role and importance of thrombus burden during
treatment of patients with STEMI.
Despite some uncertainties about the role resistant
thrombi have in mediating adverse outcomes in patients in
ASSENT-4 PCI, these observations complement informa-
tion concerning the role of thrombi and clinical outcomes
from studies evaluating adjunctive thrombectomy during
primary PCI for STEMI. Interest emerged in thrombec-
tomy when it became apparent that distal embolization was
commonly observed during primary PCI (17), and that this
was a predictor of worse outcomes. Disappointingly, neither
studies designed to minimize or prevent distal emboli using
embolic protection devices (18) nor use of mechanical
thrombectomy were associated with improved clinical out-
comes (19). Nonetheless, use of manual thrombectomy
devices appears to have a favorable effect on clinical out-
comes with a reduction in the incidence of both distal
emboli and mortality (20,21). The mechanisms responsible
for the apparent disparate results with manual thrombec-
tomy compared with mechanical thrombectomy or use of
embolic protection devices are uncertain. The observation
that the incidence of distal embolization is reduced with
mechanical thrombectomy and perfusion is improved, yet
overall survival is not changed, suggests that there are
complex interactions between the vascular and coagulation
systems that require further basic and clinical evaluation.
The observations from the ASSENT-4 PCI angiographic
study and the experience with adjunct manual thrombec-
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and/or distal embolization in influencing clinical outcomes
during therapy for STEMI is appropriate and should
continue to be pursued.
Like many potentially important observations, the find-
ings from this ASSENT-4 PCI angiographic study raise
many questions as well. Determining the exact nature of
these resistant thrombi will be important to direct appro-
priate preventive or therapeutic strategies. Other important
questions are: How generalizable are these findings? Do
they apply to all facilitated PCI strategies? These questions
are germane in that facilitated PCI strategies have employed
different thrombolytic, anticoagulant, and antiplatelet ther-
apies, yet all have failed to demonstrate superiority over
simple primary PCI for STEMI. Finally, it is much easier to
determine macroscopic evidence of thrombus (i.e., what we
see on an angiogram); but it is microvascular perfusion
coupled with intact cellular and myocyte function that
ultimately determines the benefit of any reperfusion strat-
egy. These ASSENT-4 PCI observations point us in an
important direction of clinical investigation, but we have a
long way to go before we achieve adequate understanding of
the dynamics of functional and effective reperfusion in the
setting of an acute myocardial infarction.
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